Taclonex

See also: Generic Taclonex Scalp

Taclonex is a brand name of betamethasone/calcipotriene topical, approved by the FDA in the following formulation(s):

TACLONEX (betamethasone dipropionate; calcipotriene hydrate - ointment; topical)

• 
  Manufacturer: LEO PHARM
  
  Approval date: January 9, 2006
  
  Strength(s): 0.064%;0.005% ^[RLD]

Has a generic version of Taclonex been approved?

No. There is currently no therapeutically equivalent version of Taclonex available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Taclonex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Crystalline form of a vitamin D analogue
  Patent 5,763,426
  Issued: June 9, 1998
  Inventor(s): Hansen; Erik Torngaard & Rastrup Andersen; Niels Smidt & Ringborg; Lene Hoffmeyer
  Assignee(s): Leo Pharmaceutical Products Ltd.
  The present invention relates to calcipotriol hydrate--a new crystalline form of calcipotriol--with superior technical properties and with superior stability.
  
  Patent expiration dates:
  
  
  • June 9, 2015
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Pharmaceutical composition
  Patent 6,753,013
  Issued: June 22, 2004
  Inventor(s): Erik; Didriksen & Gert; Høy
  Assignee(s): Leo Pharmaceutical Products, Ltd. A/S
  A pharmaceutical composition for dermal use, wherein the composition has a first pharmacologically active component A consisting of at least one vitamin D or vitamin D analogue, and a second pharmacologically active component B consisting of at least one corticosteroid, wherein the difference between the maximum stability pH of said first component A and the maximum stability pH of said second component B is at least 1. The composition can also have at least one solvent component C, where component C is compounds of the general formula R3 (OCH2C(R1)H)xOR2 (I), wherein x is in the range of 2-60, R1 in each of the x units independently is H or CH3, R2 is straight chain or branched C1-20alkyl or benzoyl, and R3 is H or phenylcarbonyloxy; di-(straight or branched)-C4-10alkyl esters of C4-C8dicarboxylic acids; straight or branched C12-18-alkyl benzoates; straight or branched C2-4-alkyl esters of straight or branched C10-18-alkanoic or -alkenoic acids; propylenglycol diesters with C8-14-alkanoic acids; and branched primary C18-24alkanols.
  
  Patent expiration dates:
  
  
  • January 27, 2020
    
    ✓ 
    Patent use: PSORIASIS
    ✓ 
    Drug product
  
  
  
  • January 27, 2020
    
    ✓ 
    Patent use: TREATMENT OF MODERATE PLAQUE PSORIASIS
    ✓ 
    Drug product
  
  



• 
  Crystalline form of a vitamin D analogue
  Patent RE39706
  Issued: June 26, 2007
  Inventor(s): Hansen; Erik Torngaard & Andersen; Niels Smidt Rastrup & Ringborg; Lene Hoffmeyer
  Assignee(s): Leo Pharma A/S
  The present invention relates to calcipotriol hydrate—a new crystalline form of calcipotriol—with superior technical properties and with superior stability.
  
  Patent expiration dates:
  
  
  • June 9, 2015
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Taclonex Consumer Information (Drugs.com)
• Taclonex Ointment Consumer Information (Wolters Kluwer)
• Taclonex topical Consumer Information (Cerner Multum)
• Taclonex Advanced Consumer Information (Micromedex)
• Betamethasone/Calcipotriene Ointment Consumer Information (Wolters Kluwer)
• Betamethasone/Calcipotriene Suspension Consumer Information (Wolters Kluwer)
• Betamethasone and calcipotriene topical Consumer Information (Cerner Multum)
• Betamethasone and calcipotriene Topical application Advanced Consumer Information (Micromedex)